Advertisement

Influence of Age and Comorbidity on Colorectal Cancer Screening in the Elderly

      Introduction

      Expert recommendations differ for colorectal cancer screening in the elderly. Recent studies suggest that healthy adults aged >75 years may benefit from screening. This study examined screening use and follow-up, and how they varied by health status within age strata, among a large cohort of elderly individuals in community settings.

      Methods

      A population-based, longitudinal cohort study was conducted among health plan members aged 65–89 years enrolled during 2011–2012 in three integrated healthcare systems participating in the Population-Based Research Optimizing Screening through Personalized Regimens consortium. Comorbidity measurements used the Charlson index. Analyses, conducted in 2015, comprised descriptive statistics and multivariable modeling that estimated age by comorbidity–specific percentages of patients for two outcomes: colorectal cancer screening uptake and follow-up of abnormal fecal blood tests.

      Results

      Among 846,267 patients, 72% were up-to-date with colorectal cancer screening. Of patients with a positive fecal blood test, 65% received follow-up colonoscopy within 3 months. Likelihood of being up-to-date and receiving timely follow-up was significantly lower for patients aged ≥76 years than their younger counterparts (p<0.001). Comorbidity was less influential than age and more strongly related to timely follow-up than being up-to-date. In all age groups, considerable numbers of patients with no/low comorbidity were not up-to-date or did not receive timely follow-up.

      Conclusions

      In three integrated healthcare systems, many older, relatively healthy patients were not screening up-to-date, and some relatively young, healthy patients did not receive timely follow-up. Findings suggest a need for re-evaluating age-based screening guidelines and improving screening completion among the elderly.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Preventive Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • U.S. Preventive Services Task Force
        Screening for colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement.
        Ann Intern Med. 2008; 149: 627-637https://doi.org/10.7326/0003-4819-149-9-200811040-00243
        • Levin B.
        • Lieberman D.A.
        • McFarland B.
        • et al.
        Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the U.S. Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology.
        Gastroenterology. 2008; 134: 1570-1595https://doi.org/10.1053/j.gastro.2008.02.002
        • Qaseem A.
        • Denberg T.D.
        • Hopkins R.H.
        • et al.
        Screening for colorectal cancer: a guidance statement from the American College of Physicians.
        Ann Intern Med. 2012; 156: 378-386https://doi.org/10.7326/0003-4819-156-5-201203060-00010
        • American Geriatrics Society Ethics Committee
        Health screening decisions for older adults: AGS position paper.
        J Am Geriatr Soc. 2003; 51: 270-271https://doi.org/10.1046/j.1532-5415.2003.51069.x
        • Van Hees F.
        • Habbema J.D.
        • Meester R.G.
        • Lansdorp-Vogelaar I.
        • van Ballegooijen M.
        • Zauber A.G.
        Should colorectal cancer screening be considered in the elderly persons without previous screening? A cost-effectiveness analysis.
        Ann Intern Med. 2014; 160: 750-759https://doi.org/10.7326/M13-2263
        • Cho H.
        • Klabunde C.N.
        • Yabroff K.R.
        • et al.
        Comorbidity-adjusted life expectancy: a new tool to inform recommendations for optimal screening strategies.
        Ann Intern Med. 2013; 159: 667-677https://doi.org/10.7326/0003-4819-159-10-201311190-00005
        • van Hees F.
        • Saini S.D.
        • Lansdorp-Vogelaar I.
        • et al.
        Personalizing colonoscopy screening for elderly individuals based on screening history, cancer risk, and comorbidity status could increase cost effectiveness.
        Gastroenterology. 2015; 149: 1425-1437https://doi.org/10.1053/j.gastro.2015.07.042
      1. Ortman JM, Velkoff VA, Hogan H. An Aging Nation: The Older Population in the United States. Washington, DC: U.S. Census Bureau. www.census.gov/prod/2014pubs/p25-1140.pdf. Published May 2014. Accessed August 13, 2015.

      2. National Cancer Institute. SEER stat fact sheets: colon and rectum cancer. http://seer.cancer.gov/statfacts/html/colorect.html. Accessed August 13, 2015.

        • Jiménez-Garcia R.
        • Hernandez-Barrera V.
        • Carrasco-Garrido P.
        • Gil A.
        Prevalence and predictors of breast and cervical cancer screening among Spanish women with diabetes.
        Diabetes Care. 2009; 32: 1470-1472https://doi.org/10.2337/dc09-0479
        • Kiefe C.I.
        • Funkhouser E.
        • Fouad M.N.
        • May D.S.
        Chronic disease as a barrier to breast and cervical cancer screening.
        J Gen Intern Med. 1998; 13: 357-365https://doi.org/10.1046/j.1525-1497.1998.00115.x
        • Mandelblatt J.S.
        • Gold K.
        • O’Malley A.S.
        • et al.
        Breast and cervix cancer screening among multiethnic women: role of age, health, and source of care.
        Prev Med. 1999; 28: 418-425https://doi.org/10.1006/pmed.1998.0446
        • Sewitch M.J.
        • Fournier C.
        • Dawes M.
        • et al.
        Do physician recommendations for colorectal cancer screening differ by patient age?.
        Can J Gastroenterol. 2007; 21: 435-438https://doi.org/10.1155/2007/938978
        • Walter L.C.
        • Fung K.Z.
        • Kirby K.A.
        • et al.
        Five-year downstream outcomes following prostate-specific antigen screening in older men.
        JAMA Intern Med. 2013; 173: 866-873https://doi.org/10.1001/jamainternmed.2013.323
        • Wee C.C.
        • McCarthy E.P.
        • Davis R.B.
        • Phillips R.S.
        Obesity and breast cancer screening.
        J Gen Intern Med. 2004; 19: 324-331https://doi.org/10.1111/j.1525-1497.2004.30354.x
        • Deshpande A.D.
        • McQueen A.
        • Coups E.J.
        Different effects of multiple health status indicators on breast and colorectal cancer screening in a nationally representative U.S. sample.
        Cancer Epidemiol. 2012; 36: 270-275https://doi.org/10.1016/j.canep.2011.10.001
        • Kim S.C.
        • Schneeweiss S.
        • Myers J.A.
        • Liu J.
        • Solomon D.H.
        No differences in cancer screening rates in patients with rheumatoid arthritis compared to the general population.
        Arthritis Rheum. 2012; 64: 3076-3082https://doi.org/10.1002/art.34542
        • Singal A.K.
        • Lin Y.L.
        • Kuo Y.F.
        • Riall T.
        • Goodwin J.S.
        Primary care physicians and disparities in colorectal cancer screening in the elderly.
        Health Serv Res. 2013; 48: 95-113https://doi.org/10.1111/j.1475-6773.2012.01433.x
        • Yasmeen S.
        • Xing G.
        • Morris C.
        • Chlebowski R.T.
        • Romano P.S.
        Comorbidities and mammography use interact to explain racial/ethnic disparities in breast cancer stage at diagnosis.
        Cancer. 2011; 117: 3252-3261https://doi.org/10.1002/cncr.25857
      3. IOM. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academies Press. https://iom.nationalacademies.org/Reports/2001/Crossing-the-Quality-Chasm-A-New-Health-System-for-the-21st-Century.aspx. Published 2001. Accessed August 13, 2015.

        • Dinh T.A.
        • Alperin P.
        • Walter L.C.
        • Smith R.
        Impact of comorbidity on colorectal cancer screening cost-effectiveness study in diabetic populations.
        J Gen Intern Med. 2012; 27: 730-738https://doi.org/10.1007/s11606-011-1972-6
        • Fisher D.A.
        • Judd L.
        • Sanford N.S.
        Inappropriate colorectal cancer screening: findings and implications.
        Am J Gastroenterol. 2005; 100: 2526-2530https://doi.org/10.1111/j.1572-0241.2005.00322.x
        • Leach C.R.
        • Klabunde C.N.
        • Alfano C.M.
        • Smith J.L.
        • Rowland J.H.
        Physician over-recommendation of mammography for terminally ill women.
        Cancer. 2012; 118: 27-37https://doi.org/10.1002/cncr.26233
        • Schonberg M.A.
        • McCarthy E.P.
        • Davis R.B.
        • Phillips R.S.
        • Hamel M.B.
        Breast cancer screening in women aged 80 and older: results from a national survey.
        J Am Geriatr Soc. 2004; 52: 1688-1695https://doi.org/10.1111/j.1532-5415.2004.52462.x
        • Walter L.C.
        • Bertenthal D.
        • Lindquist K.
        • Konety B.R.
        PSA screening among elderly men with limited life expectancies.
        JAMA. 2006; 296: 2336-2342https://doi.org/10.1001/jama.296.19.2336
        • Garman K.S.
        • Jeffreys A.
        • Coffman C.
        • Fisher D.A.
        Colorectal cancer screening, comorbidity, and follow-up in elderly patients.
        Am J Med Sci. 2006; 332: 159-163https://doi.org/10.1097/00000441-200610000-00001
        • Tiro J.A.
        • Kamineni A.
        • Levin T.R.
        • et al.
        The colorectal cancer screening process in community settings: a conceptual model for the Population-Based Research Optimizing Screening through Personalized Regimens Consortium.
        Cancer Epidemiol Biomarkers Prev. 2014; 23: 1-12https://doi.org/10.1158/1055-9965.EPI-13-1217
        • Charlson M.E.
        • Pompei P.
        • Ales K.L.
        • MacKenzie C.R.
        A new method of classifying comorbidity in longitudinal studies: development and validation.
        J Chronic Dis. 1987; 40: 373-383https://doi.org/10.1016/0021-9681(87)90171-8
        • Quan H.
        • Sundararajan V.
        • Halfon P.
        • et al.
        Coding algorithms for defining comorbidity in ICD-9-CM and ICD-10 administrative data.
        Med Care. 2005; 43: 1130-1139https://doi.org/10.1097/01.mlr.0000182534.19832.83
        • Tosteson A.N.
        • Beaber E.F.
        • Tiro J.
        • et al.
        Variation in screening abnormality rates and follow-up of breast, cervical and colorectal cancer screening within the PROSPR consortium.
        J Gen Intern Med. 2016; 31: 372-379https://doi.org/10.1007/s11606-015-3552-7
        • Korn E.
        • Graubard B.
        Analysis of Health Surveys.
        Wiley, New York, NY1999https://doi.org/10.1002/9781118032619
        • Graubard B.I.
        • Korn E.L.
        Predictive margins with survey data.
        Biometrics. 1999; 55: 652-659https://doi.org/10.1111/j.0006-341X.1999.00652.x
        • Saini S.D.
        • van Hees F.
        • Vijan S.
        Smarter screening for cancer: possibilities and challenges of personalization.
        JAMA. 2014; 312: 2211-2212https://doi.org/10.1001/jama.2014.13933
        • Lansdorp-Vogelaar I.
        • Gulati R.
        • Mariotto A.B.
        • et al.
        Personalizing age of cancer screening cessation based on comorbid conditions.
        Ann Intern Med. 2014; 161: 104-112https://doi.org/10.7326/M13-2867
        • Wolfson M.C.
        Health-adjusted life expectancy.
        Health Rep. 1996; 8: 41-46
        • Yabroff K.R.
        • Zapka J.
        • Klabunde C.N.
        • et al.
        Systems strategies to support cancer screening in U.S. primary care practice.
        Cancer Epidemiol Biomarkers Prev. 2011; 20: 2471-2479https://doi.org/10.1158/1055-9965.EPI-11-0783
        • Chubak J.
        • Garcia M.P.
        • Burnett-Hartman A.
        • et al.
        Time to colonoscopy after positive fecal blood test in four U.S. health care systems.
        Cancer Epidemiol Biomarkers Prev. 2016; 25: 344-350https://doi.org/10.1158/1055-9965.EPI-15-0470
        • Shapiro J.A.
        • Klabunde C.N.
        • Thompson T.D.
        • Nadel M.R.
        • Seeff L.C.
        • White A.
        Patterns of colorectal cancer test use, including CT colonography, in the 2010 National Health Interview Survey.
        Cancer Epidemiol Biomarkers Prev. 2012; 21: 895-904https://doi.org/10.1158/1055-9965.EPI-12-0192
        • Mariotto A.B.
        • Yabroff K.R.
        • Shao Y.
        • Feuer E.J.
        • Brown M.L.
        Projections of the cost of cancer care in the United States: 2010-2020.
        J Natl Cancer Inst. 2011; 103: 117-128https://doi.org/10.1093/jnci/djq495
        • Klabunde C.N.
        • Shapiro J.A.
        • Kobrin S.
        • Nadel M.R.
        • Zapka J.M.
        Colorectal cancer screening in U.S. seniors ages 76-84 years.
        J Community Health. 2015; 40: 769-779https://doi.org/10.1007/s10900-015-9998-z
        • Benning T.M.
        • Dellaert B.G.
        • Severens J.L.
        • Dirksen C.D.
        The effect of presenting information about invasive follow-up testing on individuals’ noninvasive colorectal cancer screening participation decisions: results from a discrete choice experiment.
        Value Health. 2014; 17: 578-587https://doi.org/10.1016/j.jval.2014.04.007